However, a study undertaken in patients with recurrent breast cancer expressing NMB glycoprotein (including both HER-2-positive tumors and TNBC), showed that this antibody had similar efficacy to conventional chemotherapy, with low objectives response rates of around 6 and 7%, respectively [81]. This evidence concerns the gene ERBB2 and breast cancer.